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Original Article
Tramadol versus Nalbuphine in total intravenous anaesthesia for Dilatation and
Evacuation
Khalid Maudood Siddiqui, Ursula Chohan
Department of Anaesthesia, Aga Khan University Hospital, Karachi.
Abstract
Objective: To compare the results of Tramadol with Nalbuphine for dilatation and evacuation with total intra-
venous anaesthesia technique. 
Methods: A total of 70 patients (35 in each group) were included in this prospective, double blind randomized
study. Intravenous tramadol 1.5mg/kg and nalbuphine 0.1mg/kg were compared in total intravenous anaesthe-
sia (TIVA) using a propofol infusion in patients undergoing dilatation and evacuation (D and E). Changes in
haemodynamic variables greater than 20% from the base line values were noted. 
Results: There was no difference found in haemodynamic parameters. There was statistically significant differ-
ence found (p< 0.05) in postoperative recovery between the two groups. 
Conclusion: Quality of analgesia was better in nalbuphine group but both drugs provide suitable analgesic sup-
plementation to TIVA (JPMA 57:67;2007).
Introduction
Dilatation and Evacuation is a commonly daycare
procedure in obstetrics. Due to requirement for an early dis-
charge, this procedure requires an anaesthetic technique
which can provide rapid recovery. With a better cardiovas-
cular stability and a short time to emergence from anaesthe-
sia, TIVA is considered to be better than inhalational tech-
nique for short day care procedures.1
The advantages of TIVA technique include reduction
in the potential for administration of hypoxic gas mixtures,
less environmental pollution and absence of exposure of
patients and staff to nitrous oxide and volatile agents.2
Rapid recovery of postoperative psychomotor performance
appears to be an additional advantage of TIVA. Propofol
remains the most suitable anaesthethic agent for TIVA, it
allows for rapid changes in anaesthetic depth and a rapid
clear- headed recovery.3 Analgesia is provided either with
nalbuphine or tramadol.
Nalbuphine is a partial kappa agonist / µ antagonist
opioid of phenanthrene series. It was synthesized in an
attempt to produce analgesia without the undesirable side
effects of a µ agonist, notably respiratory depression and
drug dependence. It has been observed that nalbuphine pro-
vides cardiovascular stability and there is less nausea and
vomiting when used in the TIVA technique.4
Tramadol is a mixed compound, which not only
stimulates all opioid receptors but also inhibits neuronal
nor-epinephrine uptake and serotonin release. Analgesic
doses of tramadol produce less respiratory depression than
other opioids, owing in part to its non-opioid receptor medi-
ated actions. Equiv-analgesic dose of tramadol has much
less effect on respiratory center than pethidine. It has
demonstrated that analgesic potential of tramadol relies to a
considerable extent on non-opioid receptor mechanisms.5
Tramadol is used intraoperatively in day care surgeries and
post operative analgesic requirement is reduced.6,7
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Despite these documented advantages of Tramadol,
it has never been compared with nalbuphine. This study
compares these two drugs for D and E with TIVA technique.
Methods
The study was performed at a University Hospital
after approval from Ethics Review Committee and the
human subject protection committee of the Aga Khan
University Hospital and after informed consent from the
patient. The study included all patients of child bearing age
with pregnancy of 12 to 14 weeks duration belonging to
ASA I & II group. Excluded from the study were patients
who did not give the consent, ASA III and above, previous
hypersensitivity to any of the study drugs and anticipated
difficult intubations.
It was a prospective randomized double blind study.
Total of 70 patients were included, and were randomly
divided into two groups 'A' and 'B', with 35 patients in each
group undergoing D&E. All patients had standard monitor-
ing throughout the procedure, consisting of non invasive
blood pressure (B.P) heart rate (HR), ECG and oxygen sat-
uration. 
Group A patients were given intravenous injection
Tramadol 1.5 mg/kg after rapid sequence induction with
propofol 2mg/kg, succinylcholine 1-1.5mg/kg followed by
intubation.
Group B patients received injection Nalbuphine
0.1mg/kg after rapid sequence induction with propofol
2mg/kg, succinylcholine 1-1.5mg/kg followed by intuba-
tion. The propofol dose regimen used was that described by
Roberts et al.8 The same regimen was used in both groups.
The analgesic efficacy and haemodynamic stability
was monitored, by noting any change in arterial pressure
greater than 20% of baseline value, change in heart rate
greater than of 20% of baseline and any purposeful move-
ment in response to pain was noted.
At the termination of succinylcholine action
patients were allowed to breathe spontaneously.
Respiratory rate, tidal volumes, and oxygen saturation
were continuously monitored in all patients. Heart rate,
Blood pressure, and  Spo2 were noted at induction, 1
minute after study drug either nalbuphine or tramadol,
then 2, 3 and 5 minutes and there after until the termina-
tion of surgery. To evaluate recovery time eye opening on
command, and orientation from the end of infusion were
recorded.  
The student t-test was applied for continuous vari-
ables such as HR, BP, MAP and recovery time. The chi
square test was applied for categorical variables such as,
nausea vomiting and pain score. Data analysis was conduct-
ed through statistical package of social sciences (SPSS 10).
Results
There was no statistically significant difference in
demographic values between the two groups and also in
the variables as Heart rate, Systolic and Diastolic blood
pressure, Mean arterial pressure (MAP), and oxygen sat-
uration from induction of anaesthesia to end of surgery. 
There was a statistically significant difference
between the two groups in the recovery profile. Tramadol
had a more sedating effect than nalbuphine. Patients receiv-
ing nalbuphine woke up earlier and well oriented compared
to tramadol. (Table 1 and 2).
During the study, we also evaluated the pain score by
visual analogue scale of the patients in both groups. This
was noted as (0= No pain, 1= Mild pain, 2= Moderate pain,
and 3= Severe pain. In nalbuphine group, 80% of patients
had no pain, 19% had mild pain. In the tramadol group, 51%
of patients had no pain, 48% had mild pain and no patient
complained of moderate or severe pain in both groups in
post anaesthesia recovery room (Figure).
Discussion
Total intravenous anaesthesia (TIVA) is a popular
Table 1. Haemodynamic variables
Variables Nalbuphine Tramadol p-value
Heart Rate at Baseline (min)
Systolic B.P at Baseline (mmHg)
Diastolic B.P at Baseline (mmHg)
MAP at Baseline (mmHg)
Heart Rate at Induction (min)
Systolic B.P at Induction (mmHg)
Diastolic B.P at Induction (mmHg)
MAP at Induction (mmHg)
Heart Rate at 1 to5 min after 
study drug (min)
Systolic B.P at 1 to5 min after 
study drug (mmHg)
Diastolic B.P at 1 to5 min after 
study drug  (mmHg)
MAP at 1 to5 min after study 
drug  (mmHg)
Heart Rate at 10 min after 
study drug (min)
Systolic B.P at 10 min after 
study drug (mmHg)
Diastolic B.P at 10 min after 
study drug (mmHg)
MAP at 10 min after study 
drug  (mmHg)
89.25 + 15.1
128.29 + 12.6
78.69 + 10.4
94.72 + 10.5
109.78 + 12.1
122.97 + 23.9
75.47 + 19.0
90.80 + 20.7
93.25 + 13.8
123.22 + 20.3
76.17 + 17.2
91.11 + 17.0
82.97 + 10.0
120.69 + 10.8
69.39 + 9.0
85.17 + 8.5
81.09 + 13.9
121.00 + 14.9
73.91 + 9.0
88.97 + 10.6
106.74 + 11.6
124.80 + 21.8
79.60 + 16.3
94.26 + 17.9
97.94 + 13.0
122.74 + 20.2
75.14 + 14.4
90.34 + 15.2
88.56 + 11.5
119.24 + 10.0
70.12 + 7.3
86.35 + 7.1
0.07
0.09
0.14
0.22
0.28
0.73
0.32
0.45
0.14
0.92
0.78
0.84
0.05
0.55
0.71
0.53
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Discussion
Total intravenous anaesthesia (TIVA) is a popular
and established anaesthetic technique, mainly because of
the availability of newer anaesthetic drugs with short half
lives and advances in infusion pump technology making the
administration of these drugs easier. Currently propofol is
regarded as the most suitable anaesthetic agent for TIVA
due to its short duration of action, minimal side effects and
rapid recovery profile.9,10
Ideally a short half life narcotic agent should be used
with propofol, as propofol has no analgesic properties; this
will also reduce the dose of intravenous anaesthetic, result-
ing in lesser side effects. Fentanyl11 alfentanil12 sufentanil13
and remifentanil14,15 have all been used during TIVA. In a
multicenter study of 6,161 patients, using TIVA with propo-
fol and remifentanil proved to be safe, tolerable and effec-
tive with a high degree of acceptance by the patients.16 It
was found that postoperative pain reduced with TIVA tech-
nique, and also there were reduced analgesic require-
ments.17
One of the challenges of working in a developing
country is the non-availability of newer short acting narcotics.
This diverts anaesthesiologists to look for other alternatives.
Longer acting narcotics, like pethidine and morphine, have
been used in TIVA18 and found to be safe alternatives.
Agonist-antagonist narcotics have been used instead of short
acting narcotics in both developed and less affluent countries.
Their use has been reported by a number of investigators.19
However due to undesirable side effects of pethidine
and morphine, we decided to use tramadol and nalbuphine
with TIVA, as these are not controlled drugs, and easily
available on demand. Effects of nalbuphine have not been
directly compared with tramadol, and their use in short
gynaecological and obstetrical procedures, has not been
published in literature. 
Nalbuphine is chemically related to naloxone. It has
a ceiling effect on respiratory depression and is said to cause
less nausea and vomiting compared to morphine, pethidine
or pentazocine.20 In our study in nalbuphine group we did
not encountered nausea and vomiting, although a 2-22% of
nausea has been previously reported.21 In this study, dose of
nalbuphine was 0.1mg/kg and tramadol 1.5mg/kg given as
a bolus dose. Haemodynamic stability was present in both
groups. 
Previously a double-blind investigation was under-
taken to compare the efficacy of nalbuphine and fentanyl in
the prevention of pain in patients undergoing termination of
pregnancy in day care surgery. Patients who received nal-
buphine had significantly lower pain scores compared to
fentanyl and it proved to be more satisfactory for day sur-
gery than the more commonly used fentanyl.22
Tramadol has been used clinically; it binds to µ-opi-
oid receptors with lower affinity than morphine, which sug-
gests that the antinociceptive action of tramadol may not be
due to opioid receptor binding only. Several studies have
shown evidence that tramadol inhibits the reuptake of
monoamines, as do antidepressant drugs such as
desipramine. Tramadol inhibits the reuptake of nor epineph-
rine and serotonin.23 Recently tramadol has been used with
TIVA, and results shows that it can be safely administered
pre- and intraoperatively as pre-emptive or preventive anal-
gesia without modification of the depth of anaesthesia.24
Tramadol has been preveiously used effectively for man-
agement of gyneco-obstetric pain.25
Robert's regimen8 was use for the TIVA technique.
This manual scheme was designed to achieve a blood
propofol concentration of 3-4µg/kg within five minutes.
The use of manual regiments is now replaced by Target
Controlled Infusion (TCI) pumps in developed countries,
but again these are not generally available in the developing
world. Robert's regimen was effectively used for TIVA in
our study, and no case of awareness and recall was reported
during the study.
The recovery profile in our study showed the nal-
buphine group to have early recovery from anaesthesia as
compared to the tramadol group. In a previously described
study22 nalbuphine was compared with a short acting narcot-
ic "fentanyl". The recovery profile of nalbuphine group was
not significantly different from the fentanyl group.
Our study showed that recovery from anaesthesia
was early in nalbuphine group. Tramadol caused sedation in
2.4%.26
Table 2. Recovery from anaesthesia
Variable Nalbuphine Tramadol p-value
Time to orientation from the
end of TIVA (min)
Time to opening of eyes from
the end of TIVA (min)
19.39 (5.7)
8.39 (3.0)
23.77 (7.8)
11.46 (3.8)
< 0.05
< 0.05
80
20
0 0
52
48
0 0
0
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40
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70
80
90
100
Nalbuphine Tramadol
No Pain Mild Pain Moderate Severe
Figure. Comparison of pain scores.
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Conclusion
In conclusion, both drugs were found to be satisfac-
tory for use in TIVA. In a situation where short acting nar-
cotics are not available, nalbuphine or tramadol provided
adequate analgesia in combination with propofol.
In our study, nalbuphine had a better haemodynamic
stability and an early post operative recovery with better
pain control in comparison with tramadol, Nalbuphine
would be a better choice when using TIVA technique in the
day care surgery for D and E. 
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